Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Cookies Settings

Natalie Shoolman

Wrays

2026_IP Stars Notable Practitioner.png
Position: Principal & Head of Litigation & Dispute Resolution
Rating:
  • Notable practitioner
Jurisdictions:
Languages:
English
Biography
Natalie Shoolman is a Principal and the Head of IP Litigation & Dispute Resolution at Wrays, based in Sydney, Australia.

Natalie brings over 20 years of experience advising and acting for domestic and global clients in high-stakes IP disputes and has an enviable track record of success. Natalie has advised clients across a wide range of industries and successfully led litigation across the IP spectrum, including patents, trade marks, designs, copyright, misuse of confidential information and breaches of the Australian Consumer Law.

Natalie is particularly well known for her expertise in multi-jurisdictional patent disputes across industry sectors including pharmaceuticals, biotechnology, medtech, telecommunications, mining and clean energy. Natalie has a sophisticated knowledge of the regulatory framework for prescription medicines, and the competition overlay in patent disputes, given her repeated mandates for life sciences clients.

Natalie is consistently recognised as a leading IP litigator by The Legal 500, Doyle’s Guide, IAM Patent 1000 and Best Lawyers Australia™, reflecting her high standing in the field. In the Legal 500 2026, Natalie was recognised as “strategic, thoughtful, practical and passionate about providing legal services” with a client unhesitatingly recommending Natalie “to any client for IP-related contentious and non-contentious matters”.

Natalie is known for her creative commercial strategies, for her attention to detail and for her clear, actionable guidance on complex legal and technical issues, making her a trusted adviser for Australian and international clients navigating complex IP matters, both contentious and non-contentious.

Natalie is an active contributor to the IP community and professional associations, including the American Intellectual Property Association, AIPPI, Copyright Society of Australia, AusBiotech and the Intellectual Property Society of Australia and New Zealand (IPSANZ). Natalie currently holds the position of Secretary of IPSANZ and has served for over a decade on the NSW and Trans-Tasman IPSANZ committees.

  • Year joined firm: 2022
Recent matter / case highlights

  • Amgen Inc: Wrays successfully represented global biotech leader Amgen Inc. in a landmark Australian patent case involving PCSK9 antibodies for lowering LDL cholesterol. Sanofi challenged five of Amgen’s patent applications on nearly every ground in Federal Court, but Wrays secured a complete victory, with all challenges dismissed and costs awarded. This was Australia’s first case considering the patentability of functionally defined antibodies, with the Court confirming that antibodies targeting defined epitopes are patentable. The outcome drew national and international attention, with similar disputes ongoing in the US, Europe, Japan, Israel and before the Unified Patent Court, reinforcing Wrays’ expertise in high-stakes pharmaceutical IP litigation.
  • Amgen Inc and Amgen Australia Pty Ltd: Wrays represented Amgen in landmark proceedings against Sandoz Pty Ltd over biosimilar denosumab products, Jubbonti and Wyost, challenging potential infringement of Amgen’s Australian manufacturing patents for Prolia and Xgeva. Wrays successfully obtained preliminary discovery to access confidential manufacturing documents, establishing precedent for disclosure of biosimilar production methods. Following document review, Amgen commenced patent infringement proceedings, with Sandoz filing a cross-claim for revocation. Wrays has managed Amgen’s loss-of-exclusivity strategy, prepared all pleadings, and continues to act in related cases against other biosimilar sponsors.
  • Tianqi Lithium Kwinana Pty Ltd: Wrays represents Tianqi in a section 36 entitlement dispute at IP Australia with CSIRO over a patent for extracting value from lithium mining by-products. CSIRO claims joint ownership, asserting that its employee contributed to key aspects of the invention, while Tianqi contends CSIRO made no inventive contribution. Wrays successfully secured admission of Tianqi’s expert and witness evidence, a critical procedural win ahead of the November 2025 hearing.
  • Reckitt: In early 2025, Wrays secured Reckitt Benckiser following a competitive tender process. Wrays now manages Reckitt’s Australian and Pacific Islands portfolio, covering over 840 registered trademarks and 22 registered 2D designs and is expected to undertake high-profile enforcement matters.
Key practice areas

  • Intellectual property (contentious)
  • Life sciences IP
  • Patent (contentious)
Sector expertise

  • Energy
  • FMCG
  • Life sciences
  • Mining
  • Telecommunication
Education / Alumni

  • Bachelor of Laws (First Class Honours), University of New South Wales (2003)
  • Bachelor of Science (First Class Honours), University of New South Wales (2003)
Association / Network Memberships

  • AIPLA (American Intellectual Property Law Association)
  • International Association for the Protection of Intellectual Property (AIPPI)
  • Secretary and NSW and Trans-Tasman Committee Member, IPSANZ (Intellectual Property Society of Australia and New Zealand)
  • Institute of Patent and Trade Mark Attorneys (IPTA)
  • Copyright Society of Australia (CSA)
  • AusBiotech
  • ChIPs Network
Bar Admissions
  • Admitted to the High Court of Australia, Federal Court of Australia and Supreme Court of New South Wales (2004)
Address:
Level 20, 1 Castlereagh Street
Sydney, New South Wales, 2000
Australia
Tel:+61284156526 Email:Contact this practitioner Website:https://wrays.com.au/our-people/natalie-shoolman/

Related Practitioners

  • Tyson is a senior patent and trade marks attorney at Wrays where he has worked since 2010. He specialises in helping clients align their patent portfolios with broader commercial strategies, ensuring intellectual property adds tangible value to their business. Tyson has extensive experience drafting and prosecuting patent applications, as well as providing infringement, validity and freedom-to-operate opinions across a diverse range of industries.
  • Grant has over 20 years’ experience providing strategic intellectual property advice to top-tier global pharmaceutical clients, including Merck, Amgen, Johnson & Johnson, Nestle, CRISPR Therapeutics and Zoetis. His expertise spans patent drafting and prosecution across molecular and cell biology, immunology, pharmaceuticals, cell and gene therapy, medical devices and diagnostics. He has extensive experience managing patent oppositions, including five concurrent Australian oppositions forming part of the global CRISPR gene editing litigation, and possesses specialist knowledge in securing pharmaceutical patent term extensions and advising on patent validity and infringement. His litigation support experience includes revocation proceedings in the Federal Court, including matters concerning blockbuster biologics.